Abstract
Research leading to the isolation of the plant cannabinoids during the 1960s and to the endogenous cannabinoids, during the 1990s is described. Investigations on two non-psychotropic, synthetic cannabinoids, HU-211, a neuroprotective agent and HU-308, a specific CB 2 agonist are presented.
Keywords: Cannabis, Plant cannabinoids, Endogenous cannabinoids, Non-psychotropic, Synthetic cannabinoids, HU-211, Neuroprotective, HU-308, CB2 agonist, Cannabidiol (CBD), Spectroscopy, NMR, Cannabinoids, Geranyl pyrophosphate, Cannabigerol, Cannabigerolic acid, Cannabidiol, Cannabidiolic acid, Cannabichromene, Cannabichromenic acid, Cannabielsoic acid A, Cannabinolic acid, Cannabinol, Cannabicylol, D9-THC, D8-THC, Anandamide, 2-arachidonoyl-glycerol (2-AG), HU-211 (DEXANABINOL), NMDA receptor, HU-211 DRUG DEVELOPMENT, Synthesis of HU-308, APPETITE, AIDS, commercial name dronabinol